Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00551200
Other study ID # UP1204-003 (HPN-100-003)
Secondary ID
Status Completed
Phase Phase 2
First received October 26, 2007
Last updated January 13, 2017
Start date October 2007
Est. completion date December 2008

Study information

Verified date June 2015
Source Horizon Pharma Ireland, Ltd., Dublin Ireland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether HPN-100 is safe and tolerable in subjects with Urea Cycle Disorders.


Description:

When protein is broken down in the body, nitrogen is formed. In healthy individuals, the body combines this nitrogen with other molecules to create a harmless substance called urea, which is excreted in the urine. Patients with Urea Cycle Disorders (UCD) are unable to create as much urea from nitrogen, and therefore, toxic levels of nitrogen can accumulate in the body, causing harm. To treat these patients, doctors usually have the patient consume less protein and supplement certain amino acids that may be lacking. A drug called Buphenyl® is sometimes prescribed as an adjunctive treatment for the chronic maintenance of UCD patients in order to keep ammonia levels down. Some issues with Buphenyl® include a high pill burden (up to 40 pills per day), bad taste and odor, and high sodium content. Like Buphenyl®, HPN-100 provides an alternate way for the body to dispose of nitrogen, other than through the urea cycle. Unlike Buphenyl®, HPN-100 is an odorless, tasteless, concentrated oil that does not contain large amounts of sodium.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date December 2008
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male and female patients at least 18 years old

- Signed written informed consent by patient or patient's representative

- Diagnosis of urea cycle enzyme deficiency confirmed via enzymatic or genetic testing

- Currently treated with Buphenyl® TID for a minimum of 2 weeks prior to Visit 1

- Able to perform study activities (including the ability to collect all urine in the clinic, i.e., no patients in diapers)

- Negative pregnancy test for all females of childbearing potential. All females of childbearing potential must agree to use an acceptable method of contraception throughout the study

Exclusion Criteria:

- Use of any investigational drug within 30 days of Buphenyl® Visit 1

- Active infection (viral or bacterial) or any other condition that may increase ammonia levels

- Laboratory values outside the normal range that are determined to be clinically significant by the investigator

- Any clinical or laboratory abnormality of Grade 3 or greater severity according to the Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (or for conditions not covered by the CTCAE, a severe or life-threatening toxicity); except that Grade 3 elevations in liver enzymes are allowed in an otherwise clinically stable patient

- Use of any medication known to significantly affect renal clearance (e.g., probenecid) or to increase protein catabolism (e.g., corticosteroids), or other medication (e.g., valproate) known to increase ammonia levels, within the 24 hours prior to Visit 1

- Preexisting QTc interval prolongation (> 450 msec for males or > 460 msec for females)

- Other severe chronic medical conditions

- Known hypersensitivity to PAA, PBA, or benzoate

- Creatinine levels equal to or greater than 1.5 × ULN

- Liver transplant

Study Design


Intervention

Drug:
HPN-100
Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
BUPHENYL®
BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.

Locations

Country Name City State
United States Baylor College of Medicine Houston Texas
United States University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Horizon Pharma Ireland, Ltd., Dublin Ireland

Country where clinical trial is conducted

United States, 

References & Publications (2)

Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med. 2007 May 31;356(22):2282-92. — View Citation

Shih VE. Alternative-pathway therapy for hyperammonemia. N Engl J Med. 2007 May 31;356(22):2321-2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Venous Ammonia Levels at the Peak and Mean TNUAC Time-normalized Area Under the Curve) Data were collected at pre-first dose and at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post first dose. At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone), and at steady state (1 week) after each dose escalation
Primary Number of Subjects Experienced Adverse Events during the period on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)
Primary Number of Subjects Experienced Serious Adverse Events during the period subjects on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)
Secondary Pharmacokinetics (Plasma and Urine PK Parameters of Study Drugs and Their Metabolites) measured AUC0-24 (Area under the curve from time 0 (pre-dose) to 24 hours) for each metabolite in plasma. Data were collected at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post-first dose. At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone)
Secondary Drug Preference for HPN-100 or Buphenyl® (as Assessed by Global Preference Question) End of Study
See also
  Status Clinical Trial Phase
Completed NCT02252770 - Nitric Oxide Supplementation in Argininosuccinic Aciduria N/A
Completed NCT01002469 - Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment N/A
Completed NCT00986895 - A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group Phase 1
Completed NCT01257737 - To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs) Phase 4
Recruiting NCT05671666 - Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients N/A
Completed NCT02489292 - Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002) Phase 2
Completed NCT02311283 - Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment N/A
Completed NCT00992459 - Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders Phase 3
Completed NCT00947297 - Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD) Phase 3
Completed NCT02740153 - PCORI Urea Cycle Disorder Study
Completed NCT02051049 - Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)
Completed NCT01765283 - Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Phase 1/Phase 2
Completed NCT00947544 - Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders Phase 2
Completed NCT01347073 - Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs) Phase 3
Completed NCT00718627 - Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders Phase 2
Completed NCT03797131 - Clinical Food Study to Evaluate the Effect of KB195 on Gut Nitrogen Metabolism in Patients With Urea Cycle Disorders N/A
Completed NCT01549015 - Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function N/A
Terminated NCT01541722 - Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders N/A
Completed NCT00345605 - Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder Phase 2
Recruiting NCT00237315 - Longitudinal Study of Urea Cycle Disorders